Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.35 |
| ▸ | KDM5A | P29375 | 2/20 | 0.35 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | PTGFR | P43088 | 1/20 | 0.33 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21095326 | 1.00 | DAGLA (0.40) | DAGLAGPR84KDM5APHF8KDM4C | |
| SCHEMBL21095195 | 1.00 | DAGLA (0.40) | DAGLAGPR84KDM5APHF8KDM4C | |
| SCHEMBL21095788 | 0.99 | DAGLA (0.41) | DAGLAGPR84KDM5APHF8KDM4C | |
| SCHEMBL21095227 | 0.99 | DAGLA (0.41) | DAGLAGPR84KDM5APHF8KDM4C | |
| SCHEMBL21095233 | 0.99 | DAGLA (0.41) | DAGLAGPR84KDM5APHF8KDM4C | |
| SCHEMBL21095226 | 0.99 | DAGLA (0.41) | DAGLAGPR84KDM5APHF8KDM4C | |
| SCHEMBL21095194 | 0.99 | DAGLA (0.41) | DAGLAGPR84KDM5APHF8KDM4C | |
| SCHEMBL21095461 | 0.99 | DAGLA (0.41) | DAGLAGPR84KDM5APHF8KDM4C | |
| SCHEMBL21095228 | 0.99 | DAGLA (0.41) | DAGLAGPR84KDM5APHF8KDM4C | |
| SCHEMBL21095193 | 0.97 | DAGLA (0.40) | DAGLAGPR84KDM5APHF8KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190185435-A1 | STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | SHIRE HUMAN GENETIC THERAPIES, INC. | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185435-A1 | STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | POLB, SNRPB2, HNRNPA2B1 | DAGLA 4486/4885GPR84 4512/4885KDM5A 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.